DEPARTMENT OF HEALTH AND HUMAN SERVICES Silver Spring MD 20993
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration Silver Spring MD 20993
NDA 20151 / S-059 NDA 20699 / S-100
SUPPLEMENT APPROVAL Pfizer, Inc. Attention: Denise Tindle Director, Worldwide Regulatory Strategy 445 Easter Point Road Groton, CT 06340 Dear Ms. Tindle: Please refer to your Supplemental New Drug Applications (sNDA) dated and received March 23, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Effexor (venlafaxine HCl) Tablets and Effexor XR (venlafaxine HCl) Extended-Release Capsules. These "Changes Being Effected" supplemental new drug applications provide for the addition of the following new subsection of labeling: "Drug-Laboratory Test Interactions" under Drug Interactions: Drug-Laboratory Test Interactions False-positive urine immunoassay screening tests for phencyclidine (PCP) and amphetamine have been reported in patients taking venlafaxine. This is due to lack of specificity of the screening tests. False positive test results may be expected for several days following discontinuation of venlafaxine therapy. Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish venlafaxine from PCP and amphetamine. We have completed our review of these supplemental applications, and they are approved, effective on the date of this letter, for use as recommended in the enclosed labeling text.
Reference ID: 3125969
1'$6 1'$6
If you have any questions, email CAPT Steven D. Hardeman, R.Ph., Chief, Project Management Staff at Steven.Hardeman@.
Sincerely, {See appended electronic signature page} Thomas Laughren, M.D. Director Division of Psychiatry Products Office of Drug Evaluation I Center for Drug Evaluation and Research ENCLOSURE(s): Content of Labeling
Reference ID: 3125969
--------------------------------------------------------------------------------------------------------This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. ---------------------------------------------------------------------------------------------------------
/s/ ---------------------------------------------------MITCHELL V Mathis 05/03/2012 For Dr. Laughren
Reference ID: 3125969
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- medications sold in the united states that can cause confirmed positive
- false positive and false negative results in urine drug screening tests
- commonly prescribed medications and potential false positive tipqc
- interpretation of opiate urine drug screens healthpartners
- false positive interferences of common urine drug screen iu
- false positive drug test matrix
- clinical update june 2019 what did my patient actually take an
- substances that elicit positive and false positive results using
- the author s shown below used federal funds provided by the u s
- department of health and human services silver spring md 20993
Related searches
- colorado department of health and human services
- colorado department of health and environment
- tennessee department of health and licensure
- texas health and human services child care
- texas department of health and human services
- department of health and human services forms
- health and human services michigan
- us dept of health and human services
- nevada division of health and human services
- nevada dept of health and human services
- maine department of health and human services
- tx dept of health and human services